Dr. Craig L. Slingluff, Jr. is the vice chair for research in the Department of Surgery at the Clinical Cancer Center of the University of Virginia School of Medicine. Dr. Slingluff’s expertise involves identifying the tumor antigens that T cells target, and developing personalized vaccines aimed at improving these anti-cancer immune responses in patients. Currently, he’s also leading a CRI-funded clinical trial treating patients with anti-PD-L1 and anti-CTLA-4 checkpoint immunotherapies along with the immunoadjuvant poly ICLC.
In addition to being a member of CRI’s Scientific Advisory Council, Dr. Slingluff is a member of CRI’s Clinical Leadership Committee.
The main focus of our laboratory is the identification of human tumor antigens recognized by human [killer T cells] inhopes of creating novel immunologic treatments for human cancer.
Let's spread the word about Immunotherapy! Click to share this page with your community.